According to a recent Future Market Insights analysis, the global hyperammonemia treatment market is anticipated to reach a valuation of US$ 1,318.05 Million in 2023 and US$ 2,100 Million by 2033, with a CAGR of 4.77%.The increased frequency of urea cycle diseases, as well as extensive research and development, are.
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. Company under the management and coordination of Rossini Luxembourg S.àr.l. Registered office: Via Matteo. | March 30, 2023
/PRNewswire/ Aprecia Pharmaceuticals today announced Owen Murray as its Chief Executive Officer. Murray will lead the expansion of Aprecia s offerings in.